15 March 2017 - A report on new drugs for second-line therapy for 2 diabetes: a therapeutic review update is now available for feedback from all interested stakeholders.

CADTH has previously completed an Optimal Use Report in 2010 and a subsequent update in 2013 on drug therapies for second- and third-line treatment of type 2 diabetes. Since 2013, several new drugs and a new medication class (sodium-glucose co-transporter 2 [SGLT2] inhibitors) have been released on the market in Canada. The CADTH Common Drug Review has also provided multiple recommendations for single drug technology assessments since 2013 for drugs for type 2 diabetes. Given the evolving landscape of the treatment of type 2 diabetes, an update of the previous review has been undertaken. 

This document provides the draft recommendations for second-line drug treatments for type 2 diabetes.

Read CADTH Recommendations Report